Study S000593

The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT03951753
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 117
Start: 2019-06-28
Primary completion: 2021-04-08
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Tirzepatide; DRUG:Semaglutide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: NO
Secondary identifiers: OTHER:I8F-MC-GPGT; EUDRACT_NUMBER:2018-003343-37; NIH:2018

Registered primary outcomes

Change From Baseline in Total Clamp Disposition Index (cDI) [Baseline, Week 28]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0014677	Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Heise T, Diabetes care	2023	Randomized trial	PMID 36857477 DOI	cites ClinicalTrials.gov:NCT03951753; registry reference DERIVED:36857477
R0011434	Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Heise T, The lancet. Diabetes & endocrinology	2022	Randomized trial	PMID 35468322 DOI	cites ClinicalTrials.gov:NCT03951753; registry reference DERIVED:35468322